Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (391-400 of 1,211) with videos related to

Pageof 122
Sort By:
JACC. Heart Failure|July 13, 2024
Heart Failure Drug Development Over the Eras: From the Heart Failure CollaboratoryVanessa Blumer, James L Januzzi, JoAnn Lindenfeld, et al.
Journal of the American College of Cardiology|May 13, 2024
Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal FunctionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.
Journal of the American College of Cardiology|March 9, 2019
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian Claggett, et al.
American Heart Journal|March 29, 2008
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialRachel E Anderson, Marc A Pfeffer, Jens Jakob Thune, et al.
Hypertension (Dallas, Tex. : 1979)|December 21, 2018
HFE H63D Polymorphism and the Risk for Systemic Hypertension, Myocardial Remodeling, and Adverse Cardiovascular Events in the ARIC StudySenthil Selvaraj, Sara Seidelmann, Odilson M Silvestre, et al.
Clinical Chemistry|September 14, 2022
Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF StudyPeder L Myhre, Margaret F Prescott, Brian Claggett, et al.
JACC. Heart Failure|April 4, 2016
QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection FractionJacob Joseph, Brian C Claggett, Inder S Anand, et al.
The New England Journal of Medicine|September 2, 2014
Angiotensin-neprilysin inhibition versus enalapril in heart failureJohn J V McMurray, Milton Packer, Akshay S Desai, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|May 13, 2024
Association of Cumulative Systolic Blood Pressure With Left Atrial Function in the Setting of Normal Left Atrial Size: The Atherosclerosis Risk in Communities (ARIC) StudyJeremy R Van't Hof, Romil Parikh, Ethan D Moser, et al.
European Journal of Heart Failure|June 26, 2026
Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B TrialJosephine Mansell, Xiaowen Wang, Karola S Jering, et al.
Pageof 122

Showing results (391-400 of 1,211) with videos related to

Sort By:
Pageof 122
JACC. Heart Failure|July 13, 2024
Heart Failure Drug Development Over the Eras: From the Heart Failure CollaboratoryVanessa Blumer, James L Januzzi, JoAnn Lindenfeld, et al.
Journal of the American College of Cardiology|May 13, 2024
Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal FunctionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.
Journal of the American College of Cardiology|March 9, 2019
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian Claggett, et al.
American Heart Journal|March 29, 2008
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialRachel E Anderson, Marc A Pfeffer, Jens Jakob Thune, et al.
Hypertension (Dallas, Tex. : 1979)|December 21, 2018
HFE H63D Polymorphism and the Risk for Systemic Hypertension, Myocardial Remodeling, and Adverse Cardiovascular Events in the ARIC StudySenthil Selvaraj, Sara Seidelmann, Odilson M Silvestre, et al.
Clinical Chemistry|September 14, 2022
Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF StudyPeder L Myhre, Margaret F Prescott, Brian Claggett, et al.
JACC. Heart Failure|April 4, 2016
QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection FractionJacob Joseph, Brian C Claggett, Inder S Anand, et al.
The New England Journal of Medicine|September 2, 2014
Angiotensin-neprilysin inhibition versus enalapril in heart failureJohn J V McMurray, Milton Packer, Akshay S Desai, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|May 13, 2024
Association of Cumulative Systolic Blood Pressure With Left Atrial Function in the Setting of Normal Left Atrial Size: The Atherosclerosis Risk in Communities (ARIC) StudyJeremy R Van't Hof, Romil Parikh, Ethan D Moser, et al.
European Journal of Heart Failure|June 26, 2026
Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B TrialJosephine Mansell, Xiaowen Wang, Karola S Jering, et al.
Pageof 122